Amivantamab

MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.

MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.

MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.

MADRID — In this video, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed MARIPOSA data on amivantamab in EGFR-mutated advanced lung cancer presented at ESMO Congress.

MADRID — There were “many exciting updates in EGFR” in the advanced-stage lung cancer setting at ESMO Congress, according to Julia Rotow, MD.

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.

MADRID — The addition of amivantamab to first-line chemotherapy improved outcomes for patients with advanced non-small cell lung cancer and EGFR exon 20 insertions, according to randomized phase 3 study results presented at ESMO Congress.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Today is World Lung Cancer Day.